These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31137488)

  • 61. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.
    Song DG; Ye Q; Poussin M; Liu L; Figini M; Powell DJ
    Oncotarget; 2015 Aug; 6(25):21533-46. PubMed ID: 26101914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.
    Campillo-Davo D; Versteven M; Roex G; Reu H; Heijden SV; Anguille S; Berneman ZN; Tendeloo VFIV; Lion E
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31972992
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
    Pouw NM; Westerlaken EJ; Willemsen RA; Debets R
    J Gene Med; 2007 Jul; 9(7):561-70. PubMed ID: 17471588
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 68. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
    Zhao Y; Zheng Z; Khong HT; Rosenberg SA; Morgan RA
    J Immunother; 2006; 29(4):398-406. PubMed ID: 16799335
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Paralleled comparison of vectors for the generation of CAR-T cells.
    Qin DY; Huang Y; Li D; Wang YS; Wang W; Wei YQ
    Anticancer Drugs; 2016 Sep; 27(8):711-22. PubMed ID: 27333595
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
    Chang ZL; Silver PA; Chen YY
    J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
    [TBL] [Abstract][Full Text] [Related]  

  • 73. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
    Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
    Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy.
    Kusabuka H; Fujiwara K; Tokunaga Y; Hirobe S; Nakagawa S; Okada N
    Biochem Biophys Res Commun; 2016 Apr; 473(1):73-79. PubMed ID: 26993168
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
    Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
    Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
    Harrer DC; Schuler G; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fasten the seat belt: Increasing safety of CAR T-cell therapy.
    Simon B; Uslu U
    Exp Dermatol; 2020 Nov; 29(11):1039-1045. PubMed ID: 32627228
    [TBL] [Abstract][Full Text] [Related]  

  • 78. GP100 expression is variable in intensity in melanoma.
    Mann JE; Hasson N; Su DG; Adeniran AJ; Smalley KSM; Djureinovic D; Jilaveanu LB; Schoenfeld DA; Kluger HM
    Cancer Immunol Immunother; 2024 Aug; 73(10):191. PubMed ID: 39105816
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.
    Hibler W; Merlino G; Yu Y
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.
    Wachsmann TLA; Meeuwsen MH; Remst DFG; Buchner K; Wouters AK; Hagedoorn RS; Falkenburg JHF; Heemskerk MHM
    Blood Adv; 2023 Oct; 7(20):6178-6183. PubMed ID: 37567150
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.